CervoMed Inc. (NasdaqCM: CRVO)
Health Care · Biotechnology · US
$2.24
-30.43% today · -70.2% 1Y
CervoMed Inc. (NasdaqCM: CRVO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $33.87M and employs 15 people.
Over the last twelve months the share price has lost 70.2%, trading between 2.13 and 10.00.
Tweenvest scores CervoMed Inc. across four factors: quality 46/100, value 22/100. Its strongest factor is quality.
CRVO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $33.87M
- Revenue (TTM)
- $331.30K
- P/E
- —
- EPS
- -3.19
- Dividend yield
- —
- Beta (5Y)
- -4.30
- 52-week high
- $10.00
- 52-week low
- $2.13
- Avg volume (3M)
- —
- Shares outstanding
- 15.12M
- Employees
- 15
- Next earnings
- —
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
- ISIN
- US15713L1098
- Founded
- 2010
- Listed since
- May 23, 2008
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Lite Strategy, Inc.NasdaqCM: LITS | $34.97M | $1.15 | -9.45% |
| Holy Stone Healthcare Co., Ltd.TPEX: 4194 | $34.87M | NT$7.75 | -4.32% |
| Edesa Biotech, Inc.NasdaqCM: EDSA | $34.72M | $2.57 | -26.78% |
| Biomark Diagnostics Inc.DB: 20B | $34.02M | €0.28 | -4.70% |
| Cell Source, Inc.OTCPK: CLCS | $33.63M | $0.49 | -10.45% |
| Mabion S.A.WSE: MAB | $33.59M | zł8.07 | +0.88% |
| Genetics Generation Advancement Corp.TPEX: 4160 | $33.50M | NT$38.80 | -0.26% |
| Vivoryon Therapeutics N.V.ENXTAM: VVY | $32.98M | €0.99 | -5.71% |
Figures last refreshed Oct 18, 2026.